Mene Pangalos, AstraZeneca EVP, BioPharmaceuticals R&D (via YouTube)

As­traZeneca en­lists an up­start Chi­na biotech part­ner in the wake of an R&D set­back

One of the new­ly cre­at­ed biotech up­starts in Chi­na has tied up with a Big Phar­ma backer on a dis­cov­ery deal tar­get­ed at hy­per­c­ho­les­terolemia and meta­bol­ics.

The Chi­na biotech is Choles­gen, and it’s un­like­ly you’ve ever heard much about it.

The fledg­ling biotech boot­ed up with its $14 mil­lion launch round pieced to­geth­er in ear­ly 2021 from a broad syn­di­cate that in­clud­ed AZ-CI­CC, As­traZeneca’s $1 bil­lion in­vest­ment fund cre­at­ed four years ago as the phar­ma gi­ant looked to grow its Shang­hai R&D ops and part­ner up with a new gen­er­a­tion of dis­cov­ery groups tak­ing root in the gi­ant Chi­nese mar­ket.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA